Workflow
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates

Company Performance - SpringWorks Therapeutics reported a quarterly loss of $1.11 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.81, representing an earnings surprise of -37.04% [1] - The company posted revenues of $49.09 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 23.53%, compared to year-ago revenues of $21.01 million [2] - Over the last four quarters, SpringWorks has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Movement and Outlook - SpringWorks Therapeutics shares have increased by approximately 27.9% since the beginning of the year, contrasting with the S&P 500's decline of -3.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.69 on revenues of $73.21 million, and for the current fiscal year, it is -$2.30 on revenues of $330.84 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which SpringWorks belongs, is currently in the top 32% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can significantly impact stock performance [5][8]